Tuesday, February 17, 2015

PHARMA DEALS DURING JANUARY 2015
(Part 2 out of 2)
by Medius Associates
This table lists all the major pharma collaborations, acquisitions and mergers agreed during January 2015
Licensor acquired / licensee acquirer
Product / technology
Deal type
Headline ($m)
NPS/ShireNPS specialises in rare diseases including Gattex [teduglutide] for the treatment of short bowel syndromeCorporate acquisition5,200
Foundation Medicine/RocheBroad R&D collaboration to optimise oncology treatments via Foundations genomic analysis and molecular informationMajority interest acquisition1,180
Kite Pharma/AmgenChimeric Antigen Receptor (CAR) T cell immunotherapy engineered autologous cell therapy (eACT) platform, Amgen contribute cancer targetsLicence collaboration agreement1,110
Janssen/ DepomedNucynta [tapentadol] franchise including extended release tablets and oral solutionsDivestment of US rights1,050
Esteve/ MundipharmaDiscovery and development of next generation pain products including E-52862 in P2 for neuropathic painStrategic collaboration1,000
Isis/ JanssenAntisense drugs to treat autoimmune disorders of the GI tract - local and oral therapies (3 programmes)Collaboration to discover and develop candidates835
Fedora and Meiji Seika/RocheRoche secures rights to OP0595 a beta lactamase inhibitor in P1 clinical development against multi drug resistant bacteriaLicence agreement750
Convergence/Biogen IdecIncludes a neuropathic pain portfolio with CNV 1014802 in P2 for trigeminal neuralgiaCorporate acquisition675
Trophos/RocheIncludes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injuryCorporate acquisition545
Cytos Biotechnology/ OnCoreAccess to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseasesExclusive licence522
AC Immune/ JanssenTo develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease3 year research collaboration and exclusive licence509
Neuropore Therapies/UCBTo develop and commercialise NPT200-11 and other therapeutic products for Parkinson's diseaseCollaboration agreement480
PneumRx/BTGIncludes RePneu a coil to open airways in emphysema patientsCorporate acquisition475
Phenex/GileadSmall molecules targeting FXR Farnesoid X receptor (FXR) programme Px102, Px104 in P2 development in Non-Alcoholic Steatohepatitis [NASH]Asset acquisition470
Auden Mckenzie/ActavisPurchase includes generic portfolio of 175 products making Actavis no 1 generic supplier in the UKCorporate acquisition458
Agenus/IncyteUsing Agenus' antibody discovery platform focusing on 4 checkpoint modulator programmes includes $35m equityLicence to develop and commercialise410
Aurigene /Curis2 programmes including IRAK4 Inhibitors and small molecule antagonist of programmed death [PD-L1]Collaboration and option to a licence346
Vedanta /J&JMicrobiome-based drug candidate VE202 for bowel diseases, Crohn's disease and ulcerative colitisLicence to develop anti-bacterial VE202241
OnCyte/Cardio3Acquisition of the oncology division of Celdara Medical including CM-CS1 an autologous CAR-T cell drug candidate which uses NKG2D to target tumour antigensAsset acquisition180
ZymeWorks/CelgeneDevelopment of multiple bi-specific antibodies using the Azymetric platformLicence, option and collaboration164
Novartis/AspenPurchase of the heparin based anticoagulant Mono-Embolex, with sales of €68m in 2013Asset acquisition142
 Amunix/NaiaTo develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in T2 diabetes and short bowel syndrome2 exclusive licences140
Source: BioPharmaDIVE

Haciendo click en cada uno de los links siguientes, 
accederán a los Contenidos de nuestros 
TALLERES DE CAPACITACIÓN IN COMPANY A MEDIDA:
(translator on page)

(aplicados al Sector Salud y Farma, 
con resolución de casos reales en tiempo real)







Consultas al mail: msg.latam@gmail.com
ó al TE: +5411-3532-0510


Miguel Angel Medina Casabella, MSM, MBA, SMHS .·.
CoFounder & Steering Committee Member, GW Alumni Association, Argentina Chapter, since 2009
GW The George Washington University's Representative at LatAm Forums & Fairs since 2001
The George Washington University  Medical Center's Representative for LatAm since 1998
CEO, MANAGEMENT SOLUTIONS GROUP LatAm
Work Phone: ( 0054) 11 - 3532 - 0510
Mobile Phone (Domestic): ( 011 ) 15 - 4420 - 5103
Mobile Phone (Int´l): ( 0054) 911 - 4420 - 5103
Skype: medinacasabella


MANAGEMENT SOLUTIONS GROUP LatAm ©
is an Interdisciplinary Consulting Firm whose Mission is to provide integral, operational and efficient solutions, in all areas related to:

Multicultural & CrossCultural Strategies,
Strategic Management, 
Change Management, 
Strategic Marketing
Investments, 
Education Management, 
Training

for Latin American (LatAm) Countries, focused on:

a) Health, Pharma & Biotech Industry
b) Industrial & Services' Companies.
c) Universities & Training Centers
d) Government, NGOs & NPOs
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)